Premium
Interrogating Therapeutic Manipulation of the Endocannabinoid System in Human Colon
Author(s) -
Vase Hollie Francesca,
Drew Janice Elizabeth,
Ross Ruth,
Carey Frank,
Steele Robert,
Bunton David,
Farquharson Andrew
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1123.1
Subject(s) - endocannabinoid system , cannabinoid receptor , gene knockdown , cannabidiol , trpv1 , receptor , cancer research , biology , microbiology and biotechnology , gene , medicine , biochemistry , cannabis , psychiatry , transient receptor potential channel , agonist
The endocannabinoid system (ECS) plays a role in colon inflammation and cancer. Human colon explants and a novel gene expression profiling technology, the GenomeLab System (Beckman) have been developed to investigate ECS regulation in human colon. A custom designed GeXP (Beckman) multiplex gene expression assay, the hECSplex, was developed. hECSplex gene expression signatures of EC receptors ( CNR1 , CNR2 , GPR55 and TRPV1 ), ECS enzymes ( NAPE‐PLD , GDE1 , DAGLA , DAGLB , FAAH , FAAH2 and PTGS2 ), inflammatory ( IL1B , IL10 , IL6 , LEP , TNF and SOCS3 ), signalling pathway ( ID1 , BCL2 , CFL1 , BIRC5 , TP53 , MYC and KRAS ), lipid production ( SREBF1 , ACACA ), and plasma‐membrane ( OCLN ) markers were assayed using 50ng of total RNA from human colon explants treated with either cannabidiol (CBD) or tetrahydrocannabinol (THC). Preliminary results indicate that both therapeutics regulate EC receptor expression, but notably regulate diverse expression of ECS enzymes, signalling targets and inflammatory markers. The GenomeLab System presents new opportunities to interrogate multiple components of the ECS in small colon explant tissue samples in response to novel therapeutics.